Determination of FGFR1 Functions in Cytarabine Treatment of Acute Myeloid Leukemia Through Bioinformatics Analysis

Basit Öğe Kaydı
dc.authoridBozbey Merde, Irem/0000-0002-9290-938X
dc.authoridAYKAC, Okan/0000-0002-7363-8801
dc.authoridhepokur, ceylan/0000-0001-6397-1291
dc.contributor.authorMisir, Sema
dc.contributor.authorYaman, Serap Ozer
dc.contributor.authorAykac, Okan
dc.contributor.authorAkidan, Osman
dc.contributor.authorMerde, Irem Bozbey
dc.contributor.authorHepokur, Ceylan
dc.date.accessioned2025-05-04T16:45:53Z
dc.date.available2025-05-04T16:45:53Z
dc.date.issued2024
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractAim Among the most prevalent subtypes of acute leukemia is acute myeloid leukemia (LAML). Consequently, it is essential to understand the molecular causes of LAML and find its predictive and diagnostic biomarkers. The aim of this study is to determine the molecular functions of fibroblast growth factor receptor 1(FGFR1) involved in LAML pathogenesis and its potential therapeutic effect for AML treatment.Methods The molecular docking interaction of the Cytarabine with its target FGFR1 was examined. The Gene Expression Profiling Interactive Analysis, version 2 (GEPIA2), and UALCAN tools database were used to obtain the LAML gene expression datasets. Gene functional annotation was performed to investigate the DEGs' possible role. Using the Interactive Gene database retrieval tool (STRING) and a few chosen hub modules from the GeneMANIA database, the protein-protein interaction (PPI) network were constructed. A survival analysis was performed on the effects of hub genes on the overall survival of LAML patients.Results As a result of docking, a strong interaction was observed between cytarabine and FGFR1. It has been discovered that cytarabine can reverse FGFR1 expression. The survival study results showed an association between the prognosis of AML patients and one of the central genes, FGFR1.Conclusion The expression profile and functions of FGFR1 were determined in LAML patients. It has been shown that FGFR1 can be a viable therapeutic target for LAML and a possible biomarker for diagnosis.
dc.description.sponsorshipTIMER
dc.description.sponsorshipTIMER, GEPIA, UALCAN, GeneMANIA, and STRING databases, for which the authors are grateful.
dc.identifier.doi10.2174/0115701646326324240924163955
dc.identifier.issn1570-1646
dc.identifier.issn1875-6247
dc.identifier.scopusqualityQ4
dc.identifier.urihttps://doi.org/10.2174/0115701646326324240924163955
dc.identifier.urihttps://hdl.handle.net/20.500.12418/35264
dc.identifier.wosWOS:001333964700001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofCurrent Proteomics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250504
dc.subjectAcute myeloid leukemia
dc.subjectFGFR1
dc.subjectcytarabine
dc.subjectmolecular docking
dc.titleDetermination of FGFR1 Functions in Cytarabine Treatment of Acute Myeloid Leukemia Through Bioinformatics Analysis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu